GLOW Blend
Also known as · GHK-Cu + BPC-157 + TB-500 · Skin & recovery blend
- EvidencePreclinical
- CategorySkin, tissue & recovery
- RoutesubQ
- Half-lifeSee individual components
- Form
- Co-lyophilized powder
- GHK-Cu
- 50 mg
- BPC-157
- 10 mg
- TB-500
- 10 mg
- Total peptide
- 70 mg total (5:1:1 ratio)
- Purity
- ≥98% (HPLC, per component)
- COA
- Available on request
In stock
Request pricing
Contact us for current pricing and bulk quotes.
Reserve vial →For research use only. Not for human consumption. Buyers must be affiliated with a research institution.
01 / Research summary
What the literature reports
The GLOW Blend combines GHK-Cu (50 mg), BPC-157 (10 mg), and TB-500 (10 mg) in a single lyophilized vial at a 5:1:1 ratio. Each component is researched independently for skin, connective tissue, or soft-tissue recovery.
Cellaire classifies the GLOW Blend as preclinical evidence. No published clinical trial exists for this specific three-peptide combination. Each component's individual literature is cited on its own product page.
02 / Reconstitution
Reconstitution reference
Illustrative unit math for a 70 mg vial reconstituted with 3 mL bacteriostatic water. This is not a dose recommendation.
03 / Overview
Molecular overview
The GLOW Blend is a co-lyophilized vial containing 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 (70 mg total, 5:1:1 ratio). Each peptide remains a separate molecule; there is no covalent conjugation.
GHK-Cu contributes the copper tripeptide complex active in dermal fibroblast and collagen models. BPC-157 contributes the pentadecapeptide gastric-juice fragment. TB-500 contributes the thymosin β4 actin-binding fragment.
The three-peptide combination is unstudied as a single product. Each component's individual preclinical literature is cited on its dedicated product page.
None of the components are FDA-approved. All three appear on the FDA Category 2 bulk substances review list.
04 / References